Published 8 days ago • loading... • Updated 8 days ago
Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Raised to Overweight at Cantor Fitzgerald
Summary by MarketBeat
3 Articles
3 Articles
Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Raised to Overweight at Cantor Fitzgerald
Cantor Fitzgerald upgraded Monopar Therapeutics from a "neutral" rating to an "overweight" rating and set a $119.00 price target for the company in a research report on Thursday.
Monopar Therapeutics (NASDAQ:MNPR) Issues Earnings Results
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.10, FiscalAI reports. Monopar Therapeutics Trading Up 1.9% Shares of MNPR stock traded up $1.33 on Thursday, reaching $73.06. The company’s stock had […]
Coverage Details
Total News Sources3
Leaning Left0Leaning Right1Center1Last Updated50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium







